Hypercholesterolemia and microvascular dysfunction: Interventional strategies

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Stapleton, Phoebe A ^a   Goodwill, Adam G ^a   James, Milinda E ^a   Brock, Robert W ^a   Frisbee, Jefferson C ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; SUPEROXIDE DISMUTASE; THROMBOXANE A2;

AEROBIC EXERCISE; DRUG MECHANISM; DRUG TARGETING; EXERCISE INTENSITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY DISEASE; INTERVENTION STUDY; MICROANGIOPATHY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STRATEGIC PLANNING;

EID: 78349244462     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-54     Document Type: Review

References (122)

1. What Do My Cholesterol Levels Mean? American Heart Association 2007 6-22-2009
2. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. D Lloyd-Jones R Adams M Carnethon SG De TB Ferguson K Flegal E Ford K Furie A Go K Greenlund, et al. Circulation 2009 119 21 181 10.1161/CIRCULATIONAHA.108.191261 19075105
3. The role of non-LDL:non-HDL particles in atherosclerosis. JP Segrest, Curr Diab Rep 2002 2 282 288 10.1007/s11892-002-0096-0 12643186
4. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. E Selvin TP Erlinger, Circulation 2004 110 738 743 10.1161/01.CIR.0000137913.26087.F0 15262830
5. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. H Hayakawa L Raij, J Hypertens 1999 17 611 619 10.1097/00004872-199917050-00004 10403604
6. Molecular, cellular and functional imaging of atherothrombosis. RP Choudhury V Fuster ZA Fayad, Nat Rev Drug Discov 2004 3 913 925 10.1038/nrd1548 15520814
7. Apolipoprotein E-/- mice have delayed skeletal muscle healing after hind limb ischemia-reperfusion. J Kang H Albadawi VI Patel TA Abbruzzese JH Yoo WG Austen Jr MT Watkins, J Vasc Surg 2008 48 701 708 10.1016/j.jvs.2008.04.006 18572367
8. Differential impact of familial hypercholesterolemia and combined hyperlipidemia on vascular wall and network remodeling in mice. PA Stapleton AG Goodwill ME James AC D'Audiffret JC Frisbee, Microcirculation 2010 17 47 58 10.1111/j.1549-8719.2009.00003.x 20141600
9. Familial hypercholesterolemia: current treatment and advances in management. R Huijgen MN Vissers JC Defesche PJ Lansberg JJ Kastelein BA Hutten, Expert Rev Cardiovasc Ther 2008 6 567 581 10.1586/14779072.6.4.567 18402545
10. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. M Boodhwani Y Nakai S Mieno P Voisine C Bianchi EG Araujo J Feng K Michael J Li FW Sellke, Ann Thorac Surg 2006 81 634 641 10.1016/j.athoracsur.2005.07.090 16427865
11. Early endothelial dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. MC Drolet E Plante B Battistini J Couet M Arsenault, Cardiovasc Ultrasound 2004 2 10 10.1186/1476-7120-2-10 15268763
12. Altered mechanisms of endothelium-dependent dilation in skeletal muscle arterioles with genetic hypercholesterolemia. PA Stapleton AG Goodwill ME James JC Frisbee, Am J Physiol Regul Integr Comp Physiol 2007 293 1110 R1119 17626122
13. Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. SE Wolfle C de Wit, J Vasc Res 2005 42 475 482 10.1159/000088101 16155363
14. Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. F Jiang AP Gibson GJ Dusting, Eur J Pharmacol 2001 424 141 149 10.1016/S0014-2999(01) 01140-2 11476760
15. Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia. AG Goodwill PA Stapleton ME James AC D'Audiffret JC Frisbee, Microcirculation 2008 15 621 631 10.1080/10739680802308334 18720229
16. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. K Kauser C da R Fitch C Mallari GM Rubanyi, Am J Physiol Heart Circ Physiol 2000 278 1679 H1685 10775149
17. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. SL Pfister JR Falck WB Campbell, Am J Physiol 1991 261 843 H852 1887929
18. Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. KY Stokes L Calahan JM Russell S Gurwara DN Granger, Microcirculation 2006 13 377 388 10.1080/10739680600745877 16815823
19. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. KY Stokes D Cooper A Tailor DN Granger, Free Radic Biol Med 2002 33 1026 1036 10.1016/S0891-5849(02)01015-8 12374614
20. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. L Vladimirova-Kitova T Deneva E Angelova F Nikolov B Marinov N Mateva, Clin Physiol Funct Imaging 2008 28 417 425 10.1111/j.1475-097X.2008.00825.x 18798847
21. L-Arginine inhibits xanthine oxidase-dependent endothelial dysfunction in hypercholesterolemia. CR White DA Parks RP Patel J Shelton MM Tarpey BA Freeman VM rley-Usmar, FEBS Lett 2004 561 94 98 10.1016/S0014-5793(04)00137-1 15013757
22. Role of nitric oxide in cardiovascular disease: focus on the endothelium. RO Cannon III, Clin Chem 1998 44 1809 1819 9702990
23. Hypercholesterolemia enhances 15-lipoxygenase-mediated vasorelaxation and acetylcholine-induced hypotension. NT Aggarwal SL Pfister WB Campbell, Arterioscler Thromb Vasc Biol 2008 28 2209 2215 10.1161/ATVBAHA.108.177113 18832753
24. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. HJ Avis MN Vissers EA Stein FA Wijburg MD Trip JJ Kastelein BA Hutten, Arterioscler Thromb Vasc Biol 2007 27 1803 1810 10.1161/ATVBAHA.107.145151 17569881
25. Statins: mechanism of action and effects. C Stancu A Sima, J Cell Mol Med 2001 5 378 387 10.1111/j.1582-4934.2001.tb00172.x 12067471
26. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. P Dilaveris G Giannopoulos M Riga A Synetos C Stefanadis, Curr Vasc Pharmacol 2007 5 227 237 10.2174/157016107781024091 17627566
27. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins, et al. Lancet 2005 366 1267 1278 10.1016/S0140- 6736(05)67394-1 16214597
28. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. SE Leigh AH Foster RA Whittall CS Hubbart SE Humphries, Ann Hum Genet 2008 72 485 498 10.1111/j.1469-1809.2008.00436.x 18325082
29. Familial hypercholesterolemia. JL Goldstein HH Hobbs MS Brown, The metabolic and molecular bases of inherited diseases New York: McGraw-Hill Book Co, Scriver CR, Beaudet AL, Sly WS, 2001 2863 2913
30. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. MJ McNeely KL Edwards SM Marcovina JD Brunzell AG Motulsky MA Austin, Atherosclerosis 2001 159 471 481 10.1016/S0021-9150(01)00528-7 11730829
31. Endothelial cell dysfunction: can't live with it, how to live without it. MS Goligorsky, Am J Physiol Renal Physiol 2005 288 871 F880 10.1152/ajprenal.00333.2004 15821252
32. Endothelial function and oxidative stress. H Ogita J Liao, Endothelium 2004 11 123 132 10.1080/10623320490482664 15370071
33. Exercise training improves femoral artery blood flow responses to endothelium-dependent dilators in hypercholesterolemic pigs. CR Woodman D Ingram J Bonagura MH Laughlin, Am J Physiol Heart Circ Physiol 2006 290 2362 H2368 10.1152/ajpheart.01026.2005 16399863
34. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. KY Stokes JM Russell MH Jennings JS Alexander DN Granger, Free Radic Biol Med 2007 43 22 30 10.1016/j.freeradbiomed. 2007.02.027 17561090
35. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. KE Sorensen DS Celermajer D Georgakopoulos G Hatcher DJ Betteridge JE Deanfield, J Clin Invest 1994 93 50 55 10.1172/JCI116983 8282821
36. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy. M Mietus-Snyder MJ Malloy, J Pediatr 1998 133 35 40 10.1016/S0022-3476(98)70174-X 9672507
37. Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-cholesterol diet: effect of exercise. KK Henderson JR Turk JW Rush MH Laughlin, J Appl Physiol 2004 97 1159 1168 10.1152/japplphysiol.00261.2004 15208294
38. Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of conduit coronary arteries, not arterioles. DG Ingram SC Newcomer EM Price KE Eklund RM McAllister MH Laughlin, Am J Physiol Heart Circ Physiol 2007 292 2798 H2808 10.1152/ajpheart.00899.2006 17259441
39. Comparison of resistance and conduit vessel nitric oxide-mediated vascular function in vivo: effects of exercise training. DJ Green JH Walsh A Maiorana V Burke RR Taylor JG O'Driscoll, J Appl Physiol 2004 97 749 755 10.1152/japplphysiol.00109.2004 15090480
40. Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects. JH Walsh G Yong C Cheetham GF Watts GJ O'Driscoll RR Taylor DJ Green, Eur Heart J 2003 24 1681 1689 10.1016/S0195-668X(03)00384-1 14499232
41. Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit arteries. NT Aggarwal SL Pfister KM Gauthier Y Chawengsub JE Baker WB Campbell, Am J Physiol Heart Circ Physiol 2009 296 678 H688 10.1152/ajpheart. 00777.2008 19112096
42. Interrelationship of free oxygen radicals and endothelial dysfunction - modulation by statins. S Wassmann G Nickenig, Endothelium 2003 10 23 33 10.1080/10623320303357 12699074
43. Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. SL Pfister N Spitzbarth W Edgemond WB Campbell, Am J Physiol 1996 270 1021 H1030 8780199
44. Characterization of endothelial thromboxane receptors in rabbit aorta. SL Pfister, Prostaglandins Other Lipid Mediat 2008 87 54 61 10.1016/j. prostaglandins.2008.08.002 18812232
45. Aortic thromboxane receptor deficiency alters vascular reactivity in cholesterol-fed rabbits. SL Pfister, Atherosclerosis 2006 189 358 363 10.1016/j.atherosclerosis.2006.02.004 16515789
46. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. T Kobayashi Y Tahara M Matsumoto M Iguchi H Sano T Murayama H Arai H Oida T Yurugi-Kobayashi JK Yamashita, et al. J Clin Invest 2004 114 784 794 15372102
47. Reduced structural and functional skin capillaries in familial combined hyperlipidemia affected men, associated with increased remnant-like lipoprotein cholesterol levels. ET Keulen NC Schaper AJ Houben JM van Lin I Lutgens K Rijkers GM linga-Thie TW de Bruin, Atherosclerosis 2002 163 355 362 10.1016/S0021-9150(02)00021-7 12052483
48. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. OP Pitkanen OT Raitakari H Niinikoski P Nuutila H Iida LM Voipio-Pulkki R Harkonen U Wegelius T Ronnemaa J Viikari, et al. J Am Coll Cardiol 1996 28 1705 1711 10.1016/S0735-1097(96)00376-2 8962555
49. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. PA Kaufmann T Gnecchi-Ruscone KP Schafers TF Luscher PG Camici, J Am Coll Cardiol 2000 36 103 109 10.1016/S0735-1097(00) 00697-5 10898420
50. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. BL Kasiske MP O'Donnell MP Cleary WF Keane, Kidney Int 1988 33 667 672 10.1038/ki.1988.51 3367557
51. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. N Villanova S Moscatiello S Ramilli E Bugianesi D Magalotti E Vanni M Zoli G Marchesini, Hepatology 2005 42 473 480 10.1002/hep.20781 15981216
52. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1. R Scalia JZ Appel III AM Lefer, Arterioscler Thromb Vasc Biol 1998 18 1093 1100 9672069 (Pubitemid 28323593)
53. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. KY Stokes L Calahan CM Hamric JM Russell DN Granger, Am J Physiol Heart Circ Physiol 2009 296 689 H697 10.1152/ajpheart.00962.2008 19112095
54. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. V Pasceri JS Cheng JT Willerson ET Yeh, Circulation 2001 103 2531 2534 11382718
55. Monocyte chemoattractant protein-1 in human atheromatous plaques. NA Nelken SR Coughlin D Gordon JN Wilcox, J Clin Invest 1991 88 1121 1127 10.1172/JCI115411 1843454
56. Differential Impact of Familial Hypercholesterolemia and Combined Hyperlipidemia on Vascular Wall and Network Remodeling in Mice. PA Stapleton AG Goodwill ME James AC D'Audiffret JC Frisbee, Microcirculation 2010 17 47 58 10.1111/j.1549-8719.2009.00003.x 20141600
57. Implications of early structural-functional changes in the endothelium for vascular disease. M Simionescu, Arterioscler Thromb Vasc Biol 2007 27 266 274 10.1161/01.ATV.0000253884.13901.e4 17138941
58. Protection of endothelial function: targets for nutritional and pharmacological interventions. I Sudano LE Spieker F Hermann A Flammer R Corti G Noll TF Luscher, J Cardiovasc Pharmacol 2006 47 Suppl 2 136 S150 10.1097/00005344-200606001-00008 16794451
59. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. H Hashimoto K Kitagawa H Hougaku Y Shimizu M Sakaguchi Y Nagai S Iyama H Yamanishi M Matsumoto M Hori, Circulation 2001 104 63 67 10.1161/hc2601.091705 11435339
60. The pleiotropic effects of statins. P Calabro ET Yeh, Curr Opin Cardiol 2005 20 541 546 10.1097/01.hco.0000181482.99067.bf 16234628
61. Endothelial function and oxidant stress. DG Harrison, Clin Cardiol 1997 20 I 7 9422847
62. Selective targeting of NADPH oxidase for cardiovascular protection. A Cave, Curr Opin Pharmacol 2009 9 208 213 10.1016/j.coph.2008.10.001 18973829
63. NOX5, a new "radical" player in human atherosclerosis? E Schulz T Munzel, J Am Coll Cardiol 2008 52 1810 1812 10.1016/j.jacc.2008.08.040 19022161
64. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. U Forstermann T Munzel, Circulation 2006 113 1708 1714 10.1161/CIRCULATIONAHA.105.602532 16585403
65. Vascular protection: superoxide dismutase isoforms in the vessel wall. FM Faraci SP Didion, Arterioscler Thromb Vasc Biol 2004 24 1367 1373 10.1161/01.ATV.0000133604.20182.cf 15166009
66. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Z Guo Q Ran LJ Roberts L Zhou A Richardson C Sharan D Wu H Yang, Free Radic Biol Med 2008 44 343 352 10.1016/j.freeradbiomed.2007.09.009 18215741
67. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. H Cai DG Harrison, Circ Res 2000 87 840 844 11073878
68. A role for oxidized phospholipids in atherosclerosis. JA Berliner AD Watson, N Engl J Med 2005 353 9 11 10.1056/NEJMp058118 16000351
69. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. A Mugge JH Elwell TE Peterson TG Hofmeyer DD Heistad DG Harrison, Circ Res 1991 69 1293 1300 1934359
70. Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. K Sakurai T Sawamura, J Pharmacol Sci 2003 91 182 186 10.1254/jphs.91.182 12686739
71. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. S Tsimikas ES Brilakis ER Miller JP McConnell RJ Lennon KS Kornman JL Witztum PB Berger, N Engl J Med 2005 353 46 57 10.1056/NEJMoa043175 16000355
72. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. S Kinlay, J Am Coll Cardiol 2007 49 2003 2009 10.1016/j.jacc.2007.01.083 17512355
73. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. PY Liu YW Liu LJ Lin JH Chen JK Liao, Circulation 2009 119 131 138 10.1161/CIRCULATIONAHA.108.813311 19075102
74. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. KM Maki-Petaja AD Booth FC Hall SM Wallace J Brown CM McEniery IB Wilkinson, J Am Coll Cardiol 2007 50 852 858 10.1016/j.jacc.2007.04.076 17719471
75. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. TA Pearson CM Ballantyne E Veltri A Shah S Bird J Lin E Rosenberg AM Tershakovec, Am J Cardiol 2009 103 369 374 10.1016/j.amjcard.2008.09.090 19166691
76. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. M Jasinska J Owczarek D Orszulak-Michalak, Pharmacol Rep 2007 59 483 499 18048949
77. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. C Vlachopoulos K Aznaouridis A Dagre C Vasiliadou C Masoura E Stefanadi J Skoumas C Pitsavos C Stefanadis, Eur Heart J 2007 28 2102 2109 10.1093/eurheartj/ehm247 17597050
78. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. L Grodzinska D Starzyk K Bieron A Goszcz R Korbut, Basic Clin Pharmacol Toxicol 2005 96 413 419 10.1111/j.1742-7843.2005.pto-96603.x 15910404
79. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. U Laufs, Eur J Clin Pharmacol 2003 58 719 731 12634978
80. Ezetimibe, a selective inhibitor of the transport of cholesterol. S Miura K Saku, Intern Med 2008 47 1165 1170 10.2169/internalmedicine.47.1099 18591835
81. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. JG Robinson MH Davidson, Expert Rev Cardiovasc Ther 2006 4 461 476 10.1586/14779072.4.4.461 16918265
82. Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet. P Cole X Rabasseda, Drugs Today (Barc) 2005 41 317 327 10.1358/dot.2005.41.5. 893614 16082429
83. New insights into mechanisms of statin-associated myotoxicity. P Sirvent J Mercier A Lacampagne, Curr Opin Pharmacol 2008 8 333 338 10.1016/j.coph.2007. 12.010 18243052
84. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. M Takemoto JK Liao, Arterioscler Thromb Vasc Biol 2001 21 1712 1719 10.1161/hq1101.098486 11701455
85. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. L Kalinowski LW Dobrucki V Brovkovych T Malinski, Circulation 2002 105 933 938 10.1161/hc0802.104283 11864921
86. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. R Hoffman GJ Brook M Aviram, Atherosclerosis 1992 93 105 113 10.1016/0021-9150(92)90204-T 1596293
87. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. AH Wagner T Kohler U Ruckschloss I Just M Hecker, Arterioscler Thromb Vasc Biol 2000 20 61 69 10634801
88. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. O Hussein L Minasian Y Itzkovich K Shestatski L Solomon J Zidan, Br J Clin Pharmacol 2008 65 637 645 10.1111/j.1365-2125.2007.03080.x 18241285
89. Statins targeting inflammation by lowering low-density lipoprotein? EM Tuzcu SJ Nicholls, J Am Coll Cardiol 2007 49 2010 2012 10.1016/j.jacc.2007.03. 011 17512356
90. Lipid lowering for primary prevention. S Yusuf E Lonn J Bosch, Lancet 2009 373 1152 1155 10.1016/S0140-6736(09)60357-3 19345816
91. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. PM Ridker N Rifai MA Pfeffer F Sacks E Braunwald, Circulation 1999 100 230 235 10411845
92. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. V Lahera M Goicoechea SG de Vinuesa M Miana HN de las V Cachofeiro J Luno, Curr Med Chem 2007 14 243 248 10.2174/092986707779313381 17266583
93. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. C Bustos MA Hernandez-Presa M Ortego J Tunon L Ortega F Perez C Diaz G Hernandez J Egido, J Am Coll Cardiol 1998 32 2057 2064 10.1016/S0735-1097(98)00487-2 9857893
94. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. HK Chung IK Lee H Kang JM Suh H Kim KC Park DW Kim YK Kim HK Ro M Shong, Exp Mol Med 2002 34 451 461 12526087
95. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. ML Stefanick S Mackey M Sheehan N Ellsworth WL Haskell PD Wood, N Engl J Med 1998 339 12 20 10.1056/NEJM199807023390103 9647874
96. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. WL Haskell IM Lee RR Pate KE Powell SN Blair BA Franklin CA Macera GW Heath PD Thompson A Bauman, Med Sci Sports Exerc 2007 39 1423 1434 10.1249/mss. 0b013e3180616b27 17762377 (Pubitemid 47344026)
97. Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. BA Kingwell, FASEB J 2000 14 1685 1696 10.1096/fj.99-0896rev 10973917
98. Limb blood flow during exercise is dependent on nitric oxide. AJ Maxwell E Schauble D Bernstein JP Cooke, Circulation 1998 98 369 374 9711943
99. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. JL Durstine PW Grandjean PG Davis MA Ferguson NL Alderson KD DuBose, Sports Med 2001 31 1033 1062 10.2165/00007256-200131150-00002 11735685
100. Acute moderate-intensity exercise induces vasodilation through an increase in nitric oxide bioavailiability in humans. C Goto K Nishioka T Umemura D Jitsuiki A Sakagutchi M Kawamura K Chayama M Yoshizumi Y Higashi, Am J Hypertens 2007 20 825 830 10.1016/j.amjhyper.2007.02.014 17679027
101. Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats. C de Moraes AP Davel LV Rossoni E Antunes A Zanesco, BMC Physiol 2008 8 12 10.1186/1472-6793-8- 12 18510739
102. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Y Bai W Sigala GR Adams ND Vaziri, Am J Nephrol 2009 29 213 221 10.1159/000156715 18797164
103. Characterization of inflammatory responses to eccentric exercise in humans. J Peake K Nosaka K Suzuki, Exerc Immunol Rev 2005 11 64 85 16385845
104. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. BK Pedersen MA Febbraio, Physiol Rev 2008 88 1379 1406 10.1152/physrev.90100.2007 18923185
105. The diseasome of physical inactivity - and the role of myokines in muscle - fat cross talk. BK Pedersen, J Physiol 2009 587 5559 5568 10.1113/jphysiol.2009.179515 19752112
106. Role of myokines in exercise and metabolism. BK Pedersen TC Akerstrom AR Nielsen CP Fischer, J Appl Physiol 2007 103 1093 1098 10.1152/japplphysiol. 00080.2007 17347387
107. Physiological roles of muscle-derived interleukin-6 in response to exercise. BK Pedersen CP Fischer, Curr Opin Clin Nutr Metab Care 2007 10 265 271 10.1097/MCO.0b013e3280ebb5b3 17414493
108. Exercise and the immune system: regulation, integration, and adaptation. BK Pedersen L Hoffman-Goetz, Physiol Rev 2000 80 1055 1081 10893431
109. Arthritis; the use of physical therapy as an aspect of management. EP Reese, Calif Med 1958 89 204 209 13573188
110. Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene. A Oberbach S Lehmann K Kirsch J Krist M Sonnabend A Linke A Tonjes M Stumvoll M Bluher P Kovacs, Eur J Endocrinol 2008 159 129 136 10.1530/EJE-08-0220 18469018
111. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. ET Lemos F Reis S Baptista R Pinto B Sepodes H Vala P Rocha-Pereira GC Silva N Teixeira AS Silva, et al. Nutrition 2008 25 330 9 10.1016/j.nut.2008.08.014 19062255
112. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? KR Wilund, Clin Sci (Lond) 2007 112 543 555 10.1042/CS20060368 17459004
113. The molecular machinery of Keilin's respiratory chain. PR Rich, Biochem Soc Trans 2003 31 1095 1105 10.1042/BST0311095 14641005
114. Effect of exercise on oxidative stress biomarkers. RJ Bloomer, Adv Clin Chem 2008 46 1 50 full-text 19004186
115. Antioxidants and oxidative stress in exercise. LL Ji, Proc Soc Exp Biol Med 1999 222 283 292 10.1046/j.1525-1373.1999.d01-145.x 10601887
116. Prognostic value of myeloperoxidase in patients with chest pain. ML Brennan MS Penn LF Van V Nambi MH Shishehbor RJ Aviles M Goormastic ML Pepoy ES McErlean EJ Topol, et al. N Engl J Med 2003 349 1595 1604 10.1056/NEJMoa035003 14573731
117. Role of arterial wall antioxidant defense in beneficial effects of exercise on atherosclerosis in mice. O Meilhac S Ramachandran K Chiang N Santanam S Parthasarathy, Arterioscler Thromb Vasc Biol 2001 21 1681 1688 10.1161/hq1001.097106 11597945
118. Antioxidant endogenous defense in a human model of physical stress. F Mignini D Tomassoni E Traini V Streccioni, Clin Exp Hypertens 2008 30 776 784 10.1080/07420520802572341 19021027
119. Habitual exercise and arterial aging. DR Seals CA Desouza AJ Donato H Tanaka, J Appl Physiol 2008 105 1323 1332 10.1152/japplphysiol.90553.2008 18583377
120. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. T Fukai MR Siegfried M Ushio-Fukai Y Cheng G Kojda DG Harrison, J Clin Invest 2000 105 1631 1639 10.1172/JCI9551 10841522
121. Effects of different levels of exercise volume on endothelium-dependent vasodilation: roles of nitric oxide synthase and heme oxygenase. MW Sun MF Zhong J Gu FL Qian JZ Gu H Chen, Hypertens Res 2008 31 805 816 10.1291/hypres.31.805 18633193
122. Nuclear factor kappaB signaling in atherogenesis. MP de Winther E Kanters G Kraal MH Hofker, Arterioscler Thromb Vasc Biol 2005 25 904 914 10.1161/01.ATV.0000160340.72641.87 15731497